(Chen et al. 2016) investigated the clinical significance of RAD51C in NSCLC and suggested that high RAD51C might be an independent predictor of poor efficacy in NSCLC patients receiving chemotherapy and/or radiotherapy. This evidence concerns the gene RAD51C and non-small cell lung carcinoma.